Formation of Platinum Nanocrystals on Silicon Nanotubes and Corresponding Anti-Cancer Activity in Vitro.

Biodegradable porous silicon nanotubes (pSiNTs), functionalized with primary amine moieties via the use of 3-aminopropyltriethoxysilane (APTES), is demonstrated as a template for formation of platinum nanocrystals (Pt NCs) (1-3 nm). Transmission electron microscopy-energy dispersive X-ray analysis (TEM-EDX) indicates a relatively high and tunable concentration of Pt uniformly immobilized on a given nanotube (wt % Pt: 20-60%). In vitro viability and cellular uptake studies are consistent with a time-dependent toxicity of Pt NCs-pSiNTs against HeLa cells that is influenced by the degradation kinetics of the pSiNTs; internalization of the composites inside the cells exerts cellular damage in an apoptotic manner, therefore suggesting promising future applications in anticancer treatments.

Silicon Nanotubes as Potential Therapeutic Platforms.

Silicon nanotubes (SiNTs) with unique well-defined structural morphologies have been successfully fabricated and recognized as a novel architecture in the nanoscale Si family. While the typical dendritic microstructure of mesoporous silicon prepared anodically has been exploited previously for therapeutics and biosensing, our status of utilizing SiNTs in this regard is still in its infancy. In this review, we focus on the fundamental properties of such nanotubes relevant to therapeutic applications, beginning with a description of our ability to sensitively tune the structure of a given SiNT through synthetic control and the associated detailed in vitro dissolution behavior (reflecting biodegradability). Emphasis is also placed here on the range of functional moieties available to attach to the surface of SiNTs through a summary of current studies involving surface functionalization and strategies that facilitate conjugation with molecules of interest for multiple purposes, including cell labeling, nucleotide attachment, and scaffolding of therapeutic metallic nanoparticles. Experiments addressing our ability to load the interior of a given nanotube with species capable of providing magnetic field-assisted drug delivery are also briefly described. Given the range of diverse properties demonstrated to date, we believe the future to be quite promising for employing SiNTs as therapeutic platforms.

Biogenic Nanostructured Porous Silicon as a Carrier for Stabilization and Delivery of Natural Therapeutic Species.

Nanostructured mesoporous silicon (pSi) derived from the silicon-accumulator plant Tabasheer (Bambuseae) is demonstrated to serve as a potential carrier matrix for carrying and stabilizing naturally active, but otherwise metastable, therapeutic agents. Particularly, in this study, garlic oil containing phytochemicals (namely, allicin) that are capable of inhibiting Staphylococcus aureus (S. aureus) bacterial growth were incorporated into Tabasheer-derived porous silicon. Thermogravimetric analysis (TGA) indicated that relatively high amounts of the extract (53.1 ± 2.2 wt %) loaded into pSi are possible by simple infiltration. Furthermore, by assessing the antibacterial activity of the samples using a combination technique of agar disk diffusion and turbidity assays against S. aureus, we report that biogenic porous silicon can be utilized to stabilize and enhance the therapeutic effects of garlic oil for up to 4 weeks when the samples were stored under refrigerated conditions (4 °C) and 1 week at room temperature (25 °C). Critically, under ultraviolet (UV) light (365 nm) irradiation for 24 h intervals, plant-derived pSi is shown to have superior performance in protecting garlic extracts over porous silica (pSiO2) derived from the same plant feedstock or extract-only controls. The mechanism for this effect has also been investigated.

Analytical characteristics and comparative evaluation of Aptima HCV quant Dx assay with the Abbott RealTime HCV assay and Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0.

BACKGROUND: The Aptima HCV Quant Dx assay (Aptima assay) is a fully automated quantitative assay on the Panther® system. This assay is intended for confirmation of diagnosis and monitoring of HCV RNA in plasma and serum specimens. The purpose of the testing described in this paper was to evaluate the performance of the Aptima assay. METHODS: The analytical sensitivity, analytical specificity, precision, and linearity of the Aptima assay were assessed. The performance of the Aptima assay was compared to two commercially available HCV assays; the Abbott RealTime HCV assay (Abbott assay, Abbott Labs Illinois, USA) and the Roche COBAS Ampliprep/COBAS Taqman HCV Quantitative Test v2.0 (Roche Assay, Roche Molecular Systems, Pleasanton CA, USA). The 95% Lower Limit of Detection (LoD) of the assay was determined from dilutions of the 2nd HCV WHO International Standard (NIBSC 96/798 genotype 1) and HCV positive clinical specimens in HCV negative human plasma and serum. Probit analysis was performed to generate the 95% predicted detection limits. The Lower Limit of Quantitation (LLoQ) was established for each genotype by diluting clinical specimens and the 2nd HCV WHO International Standard (NIBSC 96/798 genotype 1) in HCV negative human plasma and serum. Specificity was determined using 200 fresh and 536 frozen HCV RNA negative clinical specimens including 370 plasma specimens and 366 serum specimens. Linearity for genotypes 1 to 6 was established by diluting armored RNA or HCV positive clinical specimens in HCV negative serum or plasma from 8.08 log IU/mL to below 1 log IU/mL. Precision was tested using a 10 member panel made by diluting HCV positive clinical specimens or spiking armored RNA into HCV negative plasma and serum. A method comparison was conducted against the Abbott assay using 1058 clinical specimens and against the Roche assay using 608 clinical specimens from HCV infected patients. In addition, agreement between the Roche assay and the Aptima assay using specimens with low HCV concentrations (

Analysis of the human endogenous coregulator complexome.

Elucidation of endogenous cellular protein-protein interactions and their networks is most desirable for biological studies. Here we report our study of endogenous human coregulator protein complex networks obtained from integrative mass spectrometry-based analysis of 3290 affinity purifications. By preserving weak protein interactions during complex isolation and utilizing high levels of reciprocity in the large dataset, we identified many unreported protein associations, such as a transcriptional network formed by ZMYND8, ZNF687, and ZNF592. Furthermore, our work revealed a tiered interplay within networks that share common proteins, providing a conceptual organization of a cellular proteome composed of minimal endogenous modules (MEMOs), complex isoforms (uniCOREs), and regulatory complex-complex interaction networks (CCIs). This resource will effectively fill a void in linking correlative genomic studies with an understanding of transcriptional regulatory protein functions within the proteome for formulation and testing of future hypotheses.